Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Borgo in connection with the formation of a new mortgage company (1)
Mandate

Vinge advises Borgo in connection with the formation of a new mortgage company

September 20, 2019

Five finance companies have formed a new residential mortgage platform. Ålandsbanken, Ica Banken, Ikano Bank, Söderberg & Partners and Borgo have entered into an agreement regarding the establishment of a jointly owned mortgage company on the Swedish market.

In connection with the creation of the new residential mortgage platform, the majority of the shares in Borgo were acquired by Ålandsbanken, Ica Banken, Ikano Bank and Söderberg & Partners. Borgo’s management will assume the operational responsibility for the co‑ordination and establishment of the new mortgage company.

Vinge’s team primarily consisted of Johan Larsson, Mattias Schömer, Emma‑Stuart Beck and Malin Haag.

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

 Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026